Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
In a November 4, 2024, press release, the company highlighted preliminary DIO model data: "[P]eripherally-restricted nimacimab achieve[d] significant dose-dependent weight loss" and "[p]reliminary data shows that nimacimab achieves desired metabolic outcomes." Three days later, CEO Dhillon reinforced this on an earnings call: "We believe nimacimabs first-in-class profile as a perfectly targeting CB1 inhibitor offers the right combination of efficacy and safety." The Q3 2024 10-Q echoed the theme, touting nimacimab's potential to "positively impact metabolic disorders including obesity." This optimism escalated
Learn more about Caprylic/Capric Triglyceride Stearyl Alcohol is a type of fatty alcohol from stearic acid
Sources Pearson, S
Natural GLP-1 Versus GLP-1 Medications Prescription agonists mimic or amplify receptor signaling for longer than endogenous peptide
US$ 29.82
US$ 26.43
US$ 24.10
US$ 24.75
